In recent years, there have been reports discussing drugs that target autophagy for the treatment of NAFLD, including herbal extracts, emerging GLP-1 activators, and SGLT2 inhibitors (91). The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.